Common Contracts
1 similar Second Master Clinical Study Agreement contracts
SECOND MASTER CLINICAL STUDY AGREEMENTSecond Master Clinical Study Agreement • January 10th, 2018
This Second Master Clinical Study Agreement (“Agreement”), effective as of January 10, 2018 (“Effective Date”), sets forth the terms and conditions by and between Pharmacyclics LLC, an AbbVie Company and a Delaware Limited Liability Company (“Pharmacyclics”) and The University of Texas System for the benefit of Clinical Trials Xpress (as defined in Section 1 (c) below), The University of Texas Health Science Center at Houston; The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Tyler; The University of Texas Medical Branch at Galveston; The University of Texas Southwestern Medical Center; The University of Texas Rio Grande Valley, and The University of Texas at Austin (“Institution” or collectively, “Institutions”), each a member institution of The University of Texas System (“UT System”).
